SK332002A3 - Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents - Google Patents

Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents Download PDF

Info

Publication number: SK332002A3
Authority: SK; Slovakia
Prior art keywords: disease; vitamin; essential fatty; acid; fatty acids
Prior art date: 1999-07-14

Application number

SK33-2002A

Other languages

English (en)

Slovak (sk)

Inventor

David Frederick Horrobin

Christina Gouaille

Original Assignee

Laxdale Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-14

Filing date

2000-07-11

Publication date

2002-12-03

2000-07-11 Application filed by Laxdale Ltd filed Critical Laxdale Ltd

2002-12-03 Publication of SK332002A3 publication Critical patent/SK332002A3/sk

Links

235000004626 essential fatty acids Nutrition 0.000 title claims abstract description 68
239000003795 chemical substances by application Substances 0.000 title claims abstract description 23
239000000203 mixture Substances 0.000 title claims description 11
235000016709 nutrition Nutrition 0.000 title claims description 10
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 77
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 57
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims abstract description 53
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 39
235000019152 folic acid Nutrition 0.000 claims abstract description 39
239000011724 folic acid Substances 0.000 claims abstract description 39
229960000304 folic acid Drugs 0.000 claims abstract description 39
229940011671 vitamin b6 Drugs 0.000 claims abstract description 28
229930003779 Vitamin B12 Natural products 0.000 claims abstract description 25
235000019163 vitamin B12 Nutrition 0.000 claims abstract description 25
239000011715 vitamin B12 Substances 0.000 claims abstract description 25
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 22
235000019158 vitamin B6 Nutrition 0.000 claims abstract description 22
239000011726 vitamin B6 Substances 0.000 claims abstract description 22
150000001875 compounds Chemical class 0.000 claims abstract description 13
230000004071 biological effect Effects 0.000 claims abstract description 11
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 7
238000002360 preparation method Methods 0.000 claims description 27
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 23
235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 22
229960005135 eicosapentaenoic acid Drugs 0.000 claims description 21
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 21
YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 claims description 18
239000003963 antioxidant agent Substances 0.000 claims description 14
235000006708 antioxidants Nutrition 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 13
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 12
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 10
230000003078 antioxidant effect Effects 0.000 claims description 9
235000004867 hydroxocobalamin Nutrition 0.000 claims description 9
239000011704 hydroxocobalamin Substances 0.000 claims description 9
229960001103 hydroxocobalamin Drugs 0.000 claims description 9
208000017169 kidney disease Diseases 0.000 claims description 8
208000024172 Cardiovascular disease Diseases 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 7
208000026106 cerebrovascular disease Diseases 0.000 claims description 7
238000009472 formulation Methods 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
229940088594 vitamin Drugs 0.000 claims description 7
229930003231 vitamin Natural products 0.000 claims description 7
235000013343 vitamin Nutrition 0.000 claims description 7
239000011782 vitamin Substances 0.000 claims description 7
235000014113 dietary fatty acids Nutrition 0.000 claims description 6
239000002552 dosage form Substances 0.000 claims description 6
229930195729 fatty acid Natural products 0.000 claims description 6
239000000194 fatty acid Substances 0.000 claims description 6
150000004665 fatty acids Chemical class 0.000 claims description 6
210000001519 tissue Anatomy 0.000 claims description 6
150000003722 vitamin derivatives Chemical class 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 5
208000020925 Bipolar disease Diseases 0.000 claims description 5
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
206010012289 Dementia Diseases 0.000 claims description 5
206010028980 Neoplasm Diseases 0.000 claims description 5
208000008589 Obesity Diseases 0.000 claims description 5
208000018262 Peripheral vascular disease Diseases 0.000 claims description 5
229930003268 Vitamin C Natural products 0.000 claims description 5
229930003427 Vitamin E Natural products 0.000 claims description 5
235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
125000004494 ethyl ester group Chemical group 0.000 claims description 5
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
208000016354 hearing loss disease Diseases 0.000 claims description 5
208000027866 inflammatory disease Diseases 0.000 claims description 5
235000019136 lipoic acid Nutrition 0.000 claims description 5
239000011785 micronutrient Substances 0.000 claims description 5
235000013369 micronutrients Nutrition 0.000 claims description 5
235000020824 obesity Nutrition 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
208000020016 psychiatric disease Diseases 0.000 claims description 5
229960002663 thioctic acid Drugs 0.000 claims description 5
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
235000019154 vitamin C Nutrition 0.000 claims description 5
239000011718 vitamin C Substances 0.000 claims description 5
235000019165 vitamin E Nutrition 0.000 claims description 5
239000011709 vitamin E Substances 0.000 claims description 5
229940046009 vitamin E Drugs 0.000 claims description 5
208000024827 Alzheimer disease Diseases 0.000 claims description 4
208000012902 Nervous system disease Diseases 0.000 claims description 4
208000025966 Neurological disease Diseases 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
230000002490 cerebral effect Effects 0.000 claims description 4
235000020664 gamma-linolenic acid Nutrition 0.000 claims description 4
239000007903 gelatin capsule Substances 0.000 claims description 4
229960004488 linolenic acid Drugs 0.000 claims description 4
201000000980 schizophrenia Diseases 0.000 claims description 4
206010011878 Deafness Diseases 0.000 claims description 3
206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
208000002193 Pain Diseases 0.000 claims description 3
208000001280 Prediabetic State Diseases 0.000 claims description 3
208000009205 Tinnitus Diseases 0.000 claims description 3
206010064930 age-related macular degeneration Diseases 0.000 claims description 3
230000002526 effect on cardiovascular system Effects 0.000 claims description 3
208000030533 eye disease Diseases 0.000 claims description 3
VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 3
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 3
229960002733 gamolenic acid Drugs 0.000 claims description 3
230000010370 hearing loss Effects 0.000 claims description 3
231100000888 hearing loss Toxicity 0.000 claims description 3
210000001503 joint Anatomy 0.000 claims description 3
208000002780 macular degeneration Diseases 0.000 claims description 3
230000004060 metabolic process Effects 0.000 claims description 3
201000006417 multiple sclerosis Diseases 0.000 claims description 3
230000004770 neurodegeneration Effects 0.000 claims description 3
208000015122 neurodegenerative disease Diseases 0.000 claims description 3
201000009104 prediabetes syndrome Diseases 0.000 claims description 3
210000002345 respiratory system Anatomy 0.000 claims description 3
210000003491 skin Anatomy 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
231100000886 tinnitus Toxicity 0.000 claims description 3
YFHUZNNPPBARJW-UHFFFAOYSA-N docosa-1,3,5,7,9-pentaene Chemical compound CCCCCCCCCCCCC=CC=CC=CC=CC=C YFHUZNNPPBARJW-UHFFFAOYSA-N 0.000 claims 4
208000019901 Anxiety disease Diseases 0.000 claims 2
208000000094 Chronic Pain Diseases 0.000 claims 2
208000023105 Huntington disease Diseases 0.000 claims 2
206010026749 Mania Diseases 0.000 claims 2
208000028017 Psychotic disease Diseases 0.000 claims 2
208000017442 Retinal disease Diseases 0.000 claims 2
206010038923 Retinopathy Diseases 0.000 claims 2
206010041250 Social phobia Diseases 0.000 claims 2
208000028683 bipolar I disease Diseases 0.000 claims 2
210000001035 gastrointestinal tract Anatomy 0.000 claims 2
208000019622 heart disease Diseases 0.000 claims 2
208000026278 immune system disease Diseases 0.000 claims 2
230000002757 inflammatory effect Effects 0.000 claims 2
210000004400 mucous membrane Anatomy 0.000 claims 2
230000000926 neurological effect Effects 0.000 claims 2
230000007823 neuropathy Effects 0.000 claims 2
201000001119 neuropathy Diseases 0.000 claims 2
208000019906 panic disease Diseases 0.000 claims 2
210000005259 peripheral blood Anatomy 0.000 claims 2
239000011886 peripheral blood Substances 0.000 claims 2
208000033808 peripheral neuropathy Diseases 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
208000019116 sleep disease Diseases 0.000 claims 2
208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 claims 2
208000006011 Stroke Diseases 0.000 claims 1
230000001919 adrenal effect Effects 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
MAMJNXVNGGBHFN-UHFFFAOYSA-N docosa-1,3,5,7,9,11-hexaene Chemical compound CCCCCCCCCCC=CC=CC=CC=CC=CC=C MAMJNXVNGGBHFN-UHFFFAOYSA-N 0.000 claims 1
235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
229940090949 docosahexaenoic acid Drugs 0.000 claims 1
238000003307 slaughter Methods 0.000 claims 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 22
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 18
235000021342 arachidonic acid Nutrition 0.000 description 11
229940114079 arachidonic acid Drugs 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 8
230000000694 effects Effects 0.000 description 8
235000008160 pyridoxine Nutrition 0.000 description 7
239000011677 pyridoxine Substances 0.000 description 7
235000015097 nutrients Nutrition 0.000 description 6
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 5
235000013305 food Nutrition 0.000 description 5
235000013336 milk Nutrition 0.000 description 5
239000008267 milk Substances 0.000 description 5
210000004080 milk Anatomy 0.000 description 5
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
230000037213 diet Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
TZBGSHAFWLGWBO-ABLWVSNPSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 3
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
235000020661 alpha-linolenic acid Nutrition 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
235000020778 linoleic acid Nutrition 0.000 description 3
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
235000020660 omega-3 fatty acid Nutrition 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
235000000639 cyanocobalamin Nutrition 0.000 description 2
239000011666 cyanocobalamin Substances 0.000 description 2
229960002104 cyanocobalamin Drugs 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000004710 electron pair approximation Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
235000020774 essential nutrients Nutrition 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000005313 fatty acid group Chemical group 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
229960004232 linoleic acid Drugs 0.000 description 2
150000002632 lipids Chemical group 0.000 description 2
230000008774 maternal effect Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
235000020665 omega-6 fatty acid Nutrition 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 1
108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
102100036486 Cobalamin binding intrinsic factor Human genes 0.000 description 1
101710123904 Cobalamin binding intrinsic factor Proteins 0.000 description 1
208000027205 Congenital disease Diseases 0.000 description 1
208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
-1 DGLA Chemical compound 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
208000007984 Female Infertility Diseases 0.000 description 1
208000001362 Fetal Growth Retardation Diseases 0.000 description 1
206010070531 Foetal growth restriction Diseases 0.000 description 1
206010016880 Folate deficiency Diseases 0.000 description 1
208000010188 Folic Acid Deficiency Diseases 0.000 description 1
OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010021928 Infertility female Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000007466 Male Infertility Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
241000270295 Serpentes Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229960001570 ademetionine Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
208000030270 breast disease Diseases 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000032625 disorder of ear Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
231100000040 eye damage Toxicity 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
208000030941 fetal growth restriction Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000003929 folic acid group Chemical group 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
229960002600 icosapent ethyl Drugs 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 1
235000007635 levomefolic acid Nutrition 0.000 description 1
239000011578 levomefolic acid Substances 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
235000007672 methylcobalamin Nutrition 0.000 description 1
239000011585 methylcobalamin Substances 0.000 description 1
JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
239000000047 product Substances 0.000 description 1
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
208000017497 prostate disease Diseases 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
208000017443 reproductive system disease Diseases 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000005460 tetrahydrofolate Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Child & Adolescent Psychology (AREA)

SK33-2002A 1999-07-14 2000-07-11 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents SK332002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9916536.7A GB9916536D0 (en)	1999-07-14	1999-07-14	Nutritional or pharmaceutical compositions
PCT/GB2000/002681 WO2001003696A1 (en)	1999-07-14	2000-07-11	Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents

Publications (1)

Publication Number	Publication Date
SK332002A3 true SK332002A3 (en)	2002-12-03

Family

ID=10857244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK33-2002A SK332002A3 (en)	1999-07-14	2000-07-11	Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents

Country Status (24)

Country	Link
US (1)	US20050147665A1 (no)
EP (1)	EP1200085A1 (no)
JP (1)	JP2003504333A (no)
KR (1)	KR20020025088A (no)
CN (1)	CN1223346C (no)
AU (1)	AU6167800A (no)
BR (1)	BR0013157A (no)
CA (1)	CA2377502A1 (no)
CZ (1)	CZ200258A3 (no)
EE (1)	EE200200021A (no)
GB (1)	GB9916536D0 (no)
HK (1)	HK1042853A1 (no)
HU (1)	HUP0202342A3 (no)
IL (1)	IL147556A0 (no)
IS (1)	IS6205A (no)
MX (1)	MXPA01013210A (no)
NO (1)	NO20020090L (no)
NZ (1)	NZ516101A (no)
PL (1)	PL352185A1 (no)
RU (1)	RU2001134300A (no)
SK (1)	SK332002A3 (no)
TR (1)	TR200200045T2 (no)
WO (1)	WO2001003696A1 (no)
ZA (1)	ZA200200259B (no)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7226916B1 (en)	2000-05-08	2007-06-05	N.V. Nutricia	Preparation for the prevention and/or treatment of vascular disorders
ITMI20010129A1 (it)	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
KR20020069539A (ko) *	2001-02-26	2002-09-05	주식회사 두산	뇌세포 보호용 조성물
KR100427637B1 (ko) *	2001-06-05	2004-04-27	이인규	세포내 에너지 소비 증가제
EP1407767A4 (en) *	2001-06-18	2007-01-24	Yamada Sachiko	AGONIST MEDICINAL PREPARATIONS PPAR $ G (G)
JP2003048831A (ja)	2001-08-02	2003-02-21	Suntory Ltd	脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl)	2001-11-14	2003-05-20	Nutricia Nv	Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en)	2002-03-05	2014-05-20	Pronova Biopharma Norge As	Use of EPA and DHA in secondary prevention
ATE439127T1 (de) *	2002-06-17	2009-08-15	Medestea Res & Production S P	Langkettige ungesättigte sauerstoffhaltige verbindungen und deren verwendung im therapeutischen, kosmetischen und diätetischen bereich
DE60308891T2 (de) *	2002-06-20	2007-05-24	Astion Dermatology A/S	Neue komplexe von polyhydroxyalkanfettsäureestern und niacinamid
JP4611622B2 (ja) *	2002-07-11	2011-01-12	第一三共株式会社	血中脂質改善又は血中ホモシステイン低下のための医薬組成物
CA2492781A1 (en) *	2002-07-11	2004-01-22	Sankyo Company Limited	Medicinal composition for mitigating blood lipid or lowering blood homocystein
US20040132819A1 (en) *	2002-08-06	2004-07-08	Nancy Auestad	Appetite control method
NZ569868A (en) *	2002-09-27	2010-01-29	Martek Biosciences Corp	Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
KR20040063616A (ko) *	2003-01-08	2004-07-14	김원호	다이어트 식품용 조제
JP2005082523A (ja) *	2003-09-08	2005-03-31	Toru Hasegawa	神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬
JP4522075B2 (ja)	2003-10-29	2010-08-11	サントリーホールディングス株式会社	血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
ITMI20040069A1 (it)	2004-01-21	2004-04-21	Tiberio Bruzzese	Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
WO2005110393A1 (en) *	2004-04-16	2005-11-24	Solvay Pharmaceuticals Gmbh	Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
WO2006019140A1 (ja) *	2004-08-18	2006-02-23	Mochida Pharmaceutical Co., Ltd.	ゼリー組成物
JP4993852B2 (ja)	2004-09-17	2012-08-08	サントリーホールディングス株式会社	ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US20090149436A1 (en) *	2004-11-16	2009-06-11	Astellas Pharma Inc.	Caspase inhibitor
US20060217386A1 (en) *	2005-03-10	2006-09-28	Edwards John B	Nutritional preparations
US20060217385A1 (en) *	2005-03-10	2006-09-28	Edwards John B	Nutritional preparations
JP5967855B2 (ja)	2005-06-30	2016-08-10	サントリーホールディングス株式会社	日中活動量の低下および／又はうつ症状の改善作用を有する組成物
US20070004639A1 (en) *	2005-07-01	2007-01-04	Bodybio, Inc.	Methods and compositions for treating Parkinson's disease
EP1921928A1 (en) *	2005-08-26	2008-05-21	Nestec S.A.	Nutrition for obese patients
EP1946755B1 (en) *	2005-11-11	2017-03-15	Mochida Pharmaceutical Co., Ltd.	Jelly composition
US8367121B2 (en) *	2005-11-23	2013-02-05	Florida A & M University	Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
JP5176127B2 (ja) *	2006-01-11	2013-04-03	大正製薬株式会社	視覚機能障害の予防または改善剤
US20090311329A1 (en) *	2006-04-20	2009-12-17	Technion Research And Development Foundation Ltd	Casein micelles for nanoencapsulation of hydrophobic compounds
JP5300186B2 (ja) *	2006-08-23	2013-09-25	株式会社明治	血中ホモシステイン濃度の上昇を抑制する妊婦用の乳由来組成物
KR100832675B1 (ko) *	2006-09-22	2008-05-26	한상왕	영양 보조제
JPWO2008081989A1 (ja)	2006-12-28	2010-04-30	サントリーホールディングス株式会社	神経再生剤
US8343541B2 (en) *	2007-03-15	2013-01-01	Soft Gel Technologies, Inc.	Ubiquinol and alpha lipoic acid compositions
WO2008153220A1 (ja) *	2007-06-13	2008-12-18	Suntory Holdings Limited	血管疾患の予防又は治療剤
CN101765427A (zh) *	2007-06-26	2010-06-30	N.V.努特里奇亚	在简易精神状态检查值为24-26的受试者中改善记忆
WO2009002148A1 (en) *	2007-06-27	2008-12-31	N.V. Nutricia	Food composition for prodromal dementia patients
KR101290514B1 (ko) *	2007-10-25	2013-07-26	뉴트리 가부시키가이샤	혈중의 당, 말론디알데히드 수식 ｌｄｌ, 호모시스테인 및/또는 ｃ 반응성 단백질을 저감시키기 위한 조성물
US8343753B2 (en)	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CA2711814A1 (en) *	2008-01-10	2009-07-16	Takeda Pharmaceutical Company Limited	Capsule formulation
US20110236476A1 (en)	2008-09-02	2011-09-29	Amarin Corporation Plc.	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US8865733B2 (en) *	2008-11-06	2014-10-21	Altman Enterprises, LLC	Medication and treatment for disease
WO2010127103A1 (en)	2009-04-29	2010-11-04	Amarin Pharma, Inc.	Stable pharmaceutical composition and methods of using same
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
SG175390A1 (en)	2009-04-29	2011-12-29	Amarin Corp Plc	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SI2443246T1 (en)	2009-06-15	2018-05-31	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
SG10201405994UA (en)	2009-09-23	2014-10-30	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
AU2011215669B2 (en) *	2010-02-12	2015-06-04	HedoniaUSA, Inc.	Compositions and methods for treating depression
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en)	2010-11-29	2014-03-26	Amarin Pharma Inc	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US9216209B1 (en)	2011-06-06	2015-12-22	Kilmer S. McCully	Compositions and method for utilization of thioretinamide in therapy of degenerative diseases of aging
US8293790B2 (en)	2011-10-19	2012-10-23	Dignity Sciences Limited	Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2013070735A1 (en)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
ES2891473T3 (es)	2012-01-06	2022-01-28	Amarin Pharmaceuticals Ie Ltd	Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
WO2013142482A1 (en)	2012-03-20	2013-09-26	Particle Dynamics International, Llc	Gelling agent-based dosage form
WO2014005013A2 (en)	2012-06-29	2014-01-03	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US10123986B2 (en)	2012-12-24	2018-11-13	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en)	2012-12-24	2017-04-25	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
CN103432156A (zh) *	2013-08-30	2013-12-11	深圳奥萨医药有限公司	ω-3脂肪酸和B族维生素的药物组合物及其用途
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
GB201405033D0 (en)	2014-03-20	2014-05-07	Isis Innovation	Combination therapy
US9655910B2 (en)	2014-03-21	2017-05-23	Bodybio Inc.	Compositions and methods for treating addiction
US10052339B2 (en)	2014-03-21	2018-08-21	Bodybio Inc.	Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
US9682055B2 (en)	2014-06-04	2017-06-20	Dignity Sciences Limted	Pharmaceutical compositions comprising DGLA and use of same
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10744070B2 (en)	2015-06-19	2020-08-18	University Of Southern California	Enteral fast access tract platform system
CA2990230A1 (en)	2015-06-19	2016-12-22	University Of Southern California	Compositions and methods for modified nutrient delivery
EP3950649A1 (en) *	2015-11-23	2022-02-09	Retrotope, Inc.	Site-specific isotopic labeling of 1, 4-diene systems
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
AU2017397463B2 (en)	2016-11-03	2022-01-06	HedoniaUSA, Inc.	Compositions and methods for treating depression
TW201900160A (zh)	2017-05-19	2019-01-01	愛爾蘭商艾瑪琳製藥愛爾蘭有限公司	用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
HUE067138T2 (hu)	2018-09-24	2024-10-28	Amarin Pharmaceuticals Ie Ltd	Módszerek kardiovaszkuláris események veszélyének csökkentésére egy alanyban
CN116350616A (zh)	2019-11-12	2023-06-30	阿马里纳药物爱尔兰有限公司	降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
AU2021224854A1 (en)	2020-02-21	2022-10-06	Biojiva Llc	Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4237118A (en) *	1972-03-06	1980-12-02	Howard Alan N	Dietary supplement and dietary methods employing said supplement for the treatment of obesity
GB8719988D0 (en) *	1987-08-25	1987-09-30	Efamol Ltd	Chemical compounds
US5895652A (en) *	1996-07-29	1999-04-20	Longevity Institute International	Method of metabolic adjuvanation and cellular repair
GB9715203D0 (en) *	1997-07-19	1997-09-24	Piper Edwina M	Composition

1999
- 1999-07-14 GB GBGB9916536.7A patent/GB9916536D0/en not_active Ceased
2000
- 2000-07-11 MX MXPA01013210A patent/MXPA01013210A/es unknown
- 2000-07-11 KR KR1020017016625A patent/KR20020025088A/ko not_active Ceased
- 2000-07-11 NZ NZ516101A patent/NZ516101A/xx unknown
- 2000-07-11 CZ CZ200258A patent/CZ200258A3/cs unknown
- 2000-07-11 EP EP00948105A patent/EP1200085A1/en not_active Withdrawn
- 2000-07-11 EE EEP200200021A patent/EE200200021A/xx unknown
- 2000-07-11 RU RU2001134300/14A patent/RU2001134300A/ru not_active Application Discontinuation
- 2000-07-11 SK SK33-2002A patent/SK332002A3/sk unknown
- 2000-07-11 HK HK02104664.5A patent/HK1042853A1/zh unknown
- 2000-07-11 JP JP2001508976A patent/JP2003504333A/ja active Pending
- 2000-07-11 PL PL00352185A patent/PL352185A1/xx not_active Application Discontinuation
- 2000-07-11 AU AU61678/00A patent/AU6167800A/en not_active Abandoned
- 2000-07-11 WO PCT/GB2000/002681 patent/WO2001003696A1/en not_active Ceased
- 2000-07-11 HU HU0202342A patent/HUP0202342A3/hu unknown
- 2000-07-11 CA CA002377502A patent/CA2377502A1/en not_active Abandoned
- 2000-07-11 CN CNB008103399A patent/CN1223346C/zh not_active Expired - Fee Related
- 2000-07-11 TR TR2002/00045T patent/TR200200045T2/xx unknown
- 2000-07-11 IL IL14755600A patent/IL147556A0/xx unknown
- 2000-07-11 BR BR0013157-1A patent/BR0013157A/pt not_active IP Right Cessation
2001
- 2001-12-18 IS IS6205A patent/IS6205A/is unknown
2002
- 2002-01-08 NO NO20020090A patent/NO20020090L/no unknown
- 2002-01-11 ZA ZA200200259A patent/ZA200200259B/xx unknown
2004
- 2004-11-24 US US10/995,533 patent/US20050147665A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL147556A0 (en)	2002-08-14
BR0013157A (pt)	2002-04-02
NZ516101A (en)	2003-06-30
HK1042853A1 (zh)	2002-08-30
NO20020090D0 (no)	2002-01-08
TR200200045T2 (tr)	2002-05-21
WO2001003696A1 (en)	2001-01-18
US20050147665A1 (en)	2005-07-07
CZ200258A3 (cs)	2002-06-12
GB9916536D0 (en)	1999-09-15
NO20020090L (no)	2002-01-08
CN1223346C (zh)	2005-10-19
EP1200085A1 (en)	2002-05-02
ZA200200259B (en)	2002-12-24
PL352185A1 (en)	2003-08-11
CA2377502A1 (en)	2001-01-18
CN1361690A (zh)	2002-07-31
IS6205A (is)	2001-12-18
MXPA01013210A (es)	2004-06-03
HUP0202342A2 (hu)	2002-11-28
HUP0202342A3 (en)	2003-02-28
RU2001134300A (ru)	2003-08-27
AU6167800A (en)	2001-01-30
JP2003504333A (ja)	2003-02-04
KR20020025088A (ko)	2002-04-03
EE200200021A (et)	2003-04-15

Publication	Publication Date	Title
SK332002A3 (en)	2002-12-03	Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
US6258846B1 (en)	2001-07-10	Nutritional supplements
EP0994705B1 (en)	2004-03-31	Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides
CN103517711B (zh)	2016-07-27	可用于治疗脂质代谢障碍的组合物
EP2683373B1 (de)	2023-10-25	Orthomolekulares mittel gegen die folgen von alkoholkonsum
NZ523138A (en)	2004-09-24	Vitamin K and essential fatty acids
CN103533921A (zh)	2014-01-22	用于治疗神经外伤的方法
JP2002528507A (ja)	2002-09-03	神経疾患および病態心理学的疾患の治療および予防用の組成物
KR20110108399A (ko)	2011-10-05	50세 이상을 위한 정력, 면역성, 눈 및 뼈 건강 개선용 영양 보충물
EP2929879B1 (de)	2020-03-18	Kombinationspräparat gegen infertilität, die mit endometriose assoziiert ist
JP7012724B2 (ja)	2022-02-14	腎臓透析を受けている患者のための食餌性多量／微量栄養補給剤
US20130064924A1 (en)	2013-03-14	Nutritional supplement for use under physiologically stressful conditions
KR20110117685A (ko)	2011-10-27	대량 투여 영양 보충물의 부정적인 부작용없이 비타민 및 무기질 결핍을 해결하면서 환경 스트레스의 효과를 제거하고 면역력을 개선시키고 에너지를 개선시키는 멀티비타민/무기질 제형
AU3441500A (en)	2000-10-09	Oral combinations of hydroxocobalamin and folic acid
EP2648807A1 (de)	2013-10-16	Kombinationspräparat zur verbesserung der weiblichen fertilität
EP1835917B1 (de)	2013-03-20	Mittel, enthaltend folsäure, vitamin b6 und vitamin b12, und dessen verwendung
AU2005203518A1 (en)	2005-09-01	Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
JPH01156922A (ja)	1989-06-20	悩疾患治療用薬剤の製造方法と治療用化合物
WO2019060510A1 (en)	2019-03-28	ORAL SUPPLEMENT
EP1890689A2 (fr)	2008-02-27	Composition pour retarder le développement de la maladie d'alzheimer
AT18222U1 (de)	2024-06-15	Kit-of-parts Präparat
JP4896531B2 (ja)	2012-03-14	血中ＣｏＱ１０量を増加させる医薬組成物
JP2006104080A (ja)	2006-04-20	痛風と尿酸による血流障害の予防又は治療効果のある組成物及び健康食品。
WO2024208506A1 (de)	2024-10-10	Orale wirkstoffkombination enthaltend l-arginin, l-citrullin, selenit, sowie wasserlösliches bor
HK1188933B (en)	2017-09-29	Composition useful for the treatment of lipid metabolism disorders